Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Aug 2016 11:40

RNS Number : 8343F
Verona Pharma PLC
01 August 2016
 



 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

 

Verona Pharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Other (please specify):

 

 

3. Full name of person(s) subject to the notification obligation: iii

 

 

 

OrbiMed Private Investments VI, LP

 

 

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or

reached: v

 

July 29, 2016

 

6. Date on which issuer notified:

 

July 28, 2016

7. Threshold(s) that is/are crossed or reached: vi, vii

 

Greater than 5% ownership

 

 

 

 

 8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of

Shares

Number of

Voting

Rights

Number of shares

Number of voting rights

% of voting rights x

 

Direct

 

Direct xi

Indire ct xii

 

Direct

 

Indirect

 

 

 

GB00B06GSH43

 

 

0

 

 

0

 

 

233,492,342

 

 

233,492,342

 

 

0

 

 

9.10%

 

 

0

 

 

B: Qualifying Financial Instruments

 

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/

Conversion Period xiv

Number of voting rights that may be

acquired if the instrument is

exercised/ converted.

% of voting rights

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

 

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix,

xx

 

Nominal

 

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

233,492,342

 

9.10%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), is the sole managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors.

 

 

 

 

 

 

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

 

 

13. Additional information:

 

14. Contact name:

 

Douglas Coon

 

15. Contact telephone number:

 

212-739-6400

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBGRUPQGUG
Date   Source Headline
29th Oct 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
28th Oct 202011:01 amGNWVerona Pharma plc : Update on AIM Delisting
23rd Oct 20205:30 pmRNSVerona Pharma
22nd Oct 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
13th Oct 20207:00 amGNWVerona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
23rd Sep 20209:06 amGNWVerona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
21st Sep 20207:00 amGNWIntended Delisting and Cancellation of Ordinary Shares from Trading on AIM
17th Sep 20207:00 amGNWVerona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
16th Sep 20201:25 pmGNWVerona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
8th Sep 20207:00 amGNWVerona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
2nd Sep 20207:00 amGNWVerona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
26th Aug 202010:19 amGNWVerona Pharma plc: Grant of RADSUs and PDMR Dealings
24th Aug 20207:00 amGNWVerona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
19th Aug 20207:00 amGNWVerona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
7th Aug 20203:46 pmGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
4th Aug 20206:13 pmGNWVerona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
3rd Aug 20207:00 amGNWVerona Pharma Announces August 2020 Virtual Investor Conference Participation
30th Jul 202010:52 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
30th Jul 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
27th Jul 20207:01 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
22nd Jul 20204:50 pmGNWClosing of Financing, Issued Share Capital and Total Voting Rights
17th Jul 20205:47 pmGNWVerona Pharma plc: PDMR Dealings
17th Jul 20207:00 amGNWVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
6th Jul 20204:04 pmGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
14th May 20207:00 amGNWVerona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12th May 20201:11 pmGNWDirector/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
1st May 20205:12 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30th Apr 20207:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23rd Apr 20207:00 amGNWVerona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16th Apr 202012:12 pmGNWVerona Pharma plc: Results of AGM
8th Apr 20207:00 amGNWUpdate on AGM Procedure
31st Mar 20207:00 amGNWVerona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20th Mar 202011:28 amGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:01 pmRNSPrice Monitoring Extension
16th Mar 20205:13 pmGNW2019 Annual Report and Accounts and Notice of AGM
5th Mar 20204:01 pmGNWGrant of Restricted Stock Units and PDMR Dealings
27th Feb 20207:00 amGNWVerona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21st Feb 20207:00 amGNWVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14th Feb 20207:00 amGNWVerona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
7th Feb 20207:00 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Feb 20207:00 amGNWVerona Pharma Announces Senior Management Changes
28th Jan 20207:00 amGNWVerona Pharma to Present at LSX World Congress 2020
17th Jan 20201:06 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 20205:00 amGNWVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.